In the previous grant cycle, we have demonstrated that the development of polycystic kidney disease in the Han:SPRD rat is accompanied by abnormalities in redox metabolism, that the acid content of the diet and/or experimental modifications of the redox state have profound effects on renal cystogenesis in Han:SPRD rats and pcy mice and on renal carcinogenesis in Eker rats, and that extracellular acidification increases the production of oxidant species and the rate of somatic mutations in cultured tubular epithelial cells. We hypothesize that oxidative stress resulting from acid administration, glutathione depletion, genetically determined deficiencies of CuZn superoxide dismutase (SOD1), Mn superoxide dismutase (SOD2) or selenium dependent cellular glutathione peroxidase (GPX1), or a combination of these factors will promote cystogenesis in Pkd1 del34/+ and Pkd2 -/+ mice by increasing the rate of mutation of the wild type Pkd1 and Pkd2 genes. Conversely we hypothesize that base administration will reduce the rate of intragenic homologous recombination between tandemly repeated portions of the wild-type and mutant exons 1 within the WS25 allele and will reduce the severity of polycystic kidney disease in compound heterozygous Pkd2 -/WS25 mice. Finally, we hypothesize that the generation of oxidant species in tubular epithelial cells in response to acidification or glutathione depletion is a lipid peroxyl or alkoxyl radical and that the rate of production of this radical in response to acidification or glutathione depletion in vitro and in vivo depends on the cell fatty acid composition and affects the development of polycystic kidney disease. Measurements of tissue levels of glutathione and activities of SOD1, SOD2, and GPX1 will be performed to control for the experimental conditions. The severity of the polycystic kidney disease will be assessed by histomorphometric analysis and determinations of plasma creatinine and urea. Immunohistology, together with laser capture microdissection of individual cyst cell populations, PCR amplification, and DNA sequencing will be used to assess the molecular mechanism of cyst formation. The effect of cell fatty acid composition on the generation of oxidant species, lipid peroxyl and alkoxyl radicals, mutagenesis and cystogenesis will be studied in cell culture systems using a DCF fluorometric assay, electron paramagnetic resonance, and an SV40-based shuttle vector containing suppressor tyrosyl t-RNA as a target for mutagenesis, as well as in Pkd1 -/+ and Pkd2 -/+ mice. The main thrust of the proposed studies is directed towards the identification of pathogenetic mechanisms than can be subject to preventive and therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK044863-11
Application #
6380716
Study Section
Pathology A Study Section (PTHA)
Program Officer
Hirschman, Gladys H
Project Start
1995-09-30
Project End
2003-08-31
Budget Start
2001-09-01
Budget End
2002-08-31
Support Year
11
Fiscal Year
2001
Total Cost
$199,543
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Brosnahan, Godela M; Abebe, Kaleab Z; Moore, Charity G et al. (2018) Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis 71:666-676
Besse, Whitney; Choi, Jungmin; Ahram, Dina et al. (2018) A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum Mutat 39:378-382
Cornec-Le Gall, Emilie; Torres, Vicente E; Harris, Peter C (2018) Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. J Am Soc Nephrol 29:13-23
Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier et al. (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33:477-489
Kline, Timothy L; Edwards, Marie E; Garg, Ishan et al. (2018) Quantitative MRI of kidneys in renal disease. Abdom Radiol (NY) 43:629-638
Wang, Xiaofang; Yamada, Satsuki; LaRiviere, Wells B et al. (2017) Generation and phenotypic characterization of Pde1a mutant mice. PLoS One 12:e0181087
Grantham, Jared J; Chapman, Arlene B; Blais, Jaime et al. (2017) Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 32:969-975
Devuyst, Olivier; Chapman, Arlene B; Gansevoort, Ron T et al. (2017) Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol 28:1592-1602

Showing the most recent 10 out of 105 publications